Table 1.
The Risk of Subsequent Acquisition of Cervical and Anal HPV Infection After a Single or Multiple HPV Type at the Other Anatomic Site
| HPV Infectiona at the Secondary Site | No. of Prior HPV Infectionsb at the Primary Site | Cervical (Primary) HPV Followed by Anal (Secondary) HPV |
Anal (Primary) HPV Followed by Cervical (Secondary) HPV |
||||||
| Eventsc | Follow-upd | Hazard Ratioe (95% CI) | Hazard Ratiof (95% CI) | Eventsc | Follow-upd | Hazard Ratioe (95% CI) | Hazard Ratiof (95% CI) | ||
| Any HPV type | None | 184 | 835.9 | 1 | 354 | 1678.2 | 1 | ||
| 1 genotype | 22 | 108.0 | 17.33 (10.22–29.39) | 1 | 9 | 37.1 | 9.39 (4.76–18.52) | 1 | |
| 2 genotypes | 48 | 229.3 | 45.52 (32.65–63.46) | 2.56 (1.44–4.56) | 8 | 30.9 | 7.39 (3.60–15.14) | 0.80 (0.30–2.09) | |
| ≥3 genotypes | 107 | 468.1 | 44.72 (33.68–59.38) | 2.31 (1.32–4.04) | 28 | 110.0 | 14.20 (9.75–20.67) | 1.36 (0.62–2.96) | |
| P for trend | <.0001 | .005 | <.0001 | .18 | |||||
| HR-HPV | None | 67 | 300.9 | 1 | 140 | 644.8 | 1 | ||
| 1 genotype | 13 | 69.2 | 17.95 (9.34–34.52) | 1 | 4 | 16.2 | 10.62 (3.84–29.36) | 1 | |
| 2 genotypes | 14 | 66.4 | 26.18 (14.06–48.75) | 1.74 (0.77–3.91) | 2 | 7.5 | 3.97 (0.97–16.24) | 0.33 (0.06–1.88) | |
| ≥3 genotypes | 53 | 234.6 | 41.77 (26.52–65.81) | 2.46 (1.25–4.84) | 8 | 26.9 | 12.77 (6.08–26.80) | 1.79 (0.52–6.14) | |
| P for trend | <.0001 | .002 | <.0001 | .38 | |||||
| LR-HPVg | None | 117 | 535.0 | 1 | 214 | 1033.4 | 1 | ||
| 1 genotype | 9 | 38.9 | 16.24 (6.57–40.16) | 1 | 5 | 20.9 | 8.50 (3.41–21.15) | 1 | |
| 2 genotypes | 34 | 163.0 | 64.14 (43.08–95.47) | 3.19 (1.40–7.29) | 6 | 23.4 | 10.07 (4.33–23.44) | 1.32 (0.33–5.23) | |
| ≥3 genotypes | 54 | 233.6 | 47.46 (32.94–68.37) | 2.17 (0.90–5.27) | 20 | 83.2 | 14.87 (9.64–22.93) | 1.03 (0.37–2.87) | |
| P for trend | <.0001 | .56 | <.0001 | .38 | |||||
| HR-HPV other than HPV-16, 18 | None | 47 | 211.8 | 1 | 114 | 521.2 | 1 | ||
| 1 genotype | 10 | 44.7 | 22.00 (10.29–47.00) | 1 | 3 | 12.4 | 11.52 (3.61–36.78) | 1 | |
| 2 genotypes | 11 | 54.2 | 31.58 (15.74–63.35) | 1.59 (0.66–3.85) | 2 | 7.5 | 5.33 (1.28–22.18) | 0.54 (0.10–2.89) | |
| ≥3 genotypes | 36 | 165.5 | 37.39 (21.35–65.49) | 1.80 (0.83–3.90) | 5 | 17.1 | 9.41 (3.70–23.95) | 1.27 (0.32–5.07) | |
| P for trend | <.0001 | .09 | <.0001 | .78 | |||||
| HPV-16, 18 | None | 20 | 89.1 | 1 | 26 | 123.6 | 1 | ||
| 1 genotype | 3 | 24.5 | 13.25 (3.43–51.22) | 1 | 1 | 3.8 | 6.60 (0.74–58.66) | 1 | |
| ≥2 genotypes | 20 | 81.2 | 26.91 (13.76–52.63) | 6.44 (0.96–43.03) | 3 | 9.8 | 13.94 (3.87–50.23) | 1.46 (0.10–21.03) | |
| α9/α11 | None | 36 | 167.4 | 1 | 70 | 323.7 | 1 | ||
| 1 genotype | 8 | 46.0 | 18.19 (7.59–43.57) | 1 | 0 | .0 | N/A | 1 | |
| ≥2 genotypes | 40 | 192.7 | 51.03 (29.81–87.34) | 3.13 (1.13–8.62) | 7 | 23.3 | 20.47 (9.27–45.20) | N/A | |
| α3/α15 | None | 57 | 254.3 | 1 | 94 | 467.0 | 1 | ||
| 1 genotype | 2 | 8.7 | 3.82 (0.49–30.01) | 1 | 4 | 16.9 | 12.94 (4.64–36.08) | 1 | |
| ≥2 genotypes | 37 | 171.5 | 45.36 (28.35–72.58) | 6.17 (0.92–41.20) | 12 | 44.6 | 19.62 (10.89–35.35) | 1.24 (0.40–3.88) | |
| α5/α6 | None | 28 | 138.1 | 1 | 68 | 349.0 | 1 | ||
| 1 genotype | 4 | 18.6 | 34.48 (11.09–107.24) | 1 | 0 | .0 | N/A | 1 | |
| ≥2 genotypes | 32 | 142.5 | 47.35 (27.02–82.99) | 1.09 (0.39–3.03) | 5 | 20.5 | 6.73 (2.65–17.08) | N/A | |
| α7 | None | 36 | 161.3 | 1 | 64 | 290.1 | 1 | ||
| 1 genotype | 4 | 17.3 | 27.63 (8.36–91.34) | 1 | 4 | 16.2 | 27.46 (9.88–76.31) | 1 | |
| ≥2 genotypes | 24 | 96.1 | 39.52 (21.15–73.86) | 1.66 (0.54–5.12) | 1 | 3.3 | 2.07 (0.28–15.34) | 0.16 (0.03–0.95) | |
| α1/α8/α10/α13 | None | 27 | 114.8 | 1 | 58 | 248.4 | 1 | ||
| 1 genotype | 4 | 17.4 | 25.30 (5.81–110.19) | 1 | 1 | 4.0 | 4.79 (0.65–35.58) | 1 | |
| ≥2 genotypes | 22 | 94.6 | 40.96 (21.18–79.24) | 3.38 (0.42–27.11) | 11 | 49.1 | 12.52 (6.38–24.60) | 2.78 (0.26–29.96) | |
NOTE. High-risk (oncogenic) types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; possibly oncogenic types 26, 34, 53, 66, 69, 70, 73, and 82; nononcogenic types 6, 11, 40, 42, 44, 54, 61, 72, 81, and 89; undetermined-risk types 62, 67, 71, 83, and 84. α-Papillomavirus species: species 1 comprises types 42 and 89; species 3 comprises types 61, 62, 81, 83, and 84; species 5 comprises types 51 and 82; species 6 comprises types 53, 56, and 66; species 7 comprises types 18, 39, 45, 59, 68, and 70; species 9 comprises types 16, 31, 33, 35, 52, 58, and 67; species 10 comprises types 6, 11, and 44; species 11 comprises types 34 and 73; and species 13 comprises type 54.
CI, confidence interval; HPV, human papillomavirus; HR-HPV, high-risk HPV; LR-HPV, low-risk HPV; N/A, not available.
Incident (detected at a visit other than the first) HPV infection at the secondary site.
At least 1 of the genotypes at the primary site is concordant with the HPV infection at the secondary site.
The number of incident HPV infections at the secondary site after same-type HPV infections at the primary site during the study period.
Cumulative follow-up (months) across all participants/visits for the indicated exposure group.
Reference: no HPV infection at the primary site. Adjusted for age of participants at study entry and prior HPV coinfection at the secondary site.
Reference: single-type HPV infection at the primary site. Participants with no prior HPV infection at the primary site are excluded. Adjusted for age of participants at study entry and prior HPV coinfection at the secondary site.
Includes possibly oncogenic, nononcogenic, and undetermined-risk HPV types.